Concepedia
Statistics
Publications
42
Citations
4.1K
H-Index
30
Active since
1973
Affiliations
Wilmington University(Current)
DuPont (United States)
Experimental Station
Incyte (United States)
Janssen (United States)
James D. Rodgers is an author at Wilmington University specializing in pharmacology, medicinal chemistry, and drug discovery.
Publications per year
1973–2015
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
Alfonso Quintás‐Cardama, Kris Vaddi, Phillip Liu et al. · Blood · 2010 · 827 citations
Medicine, Hematology, Pharmacology +11
Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
Jordan S. Fridman, Peggy Scherle, Robert J. Collins et al. · The Journal of Immunology · 2010 · 463 citations · Full text
Medicine, Immunology, Pharmacology +17
Electrochemical Oxidation of Chlorinated Phenols
James D. Rodgers, Wojciech Jȩdral, Nigel J. Bunce · Environmental Science & Technology · 1999 · 325 citations
Natural Sciences, Environmental Engineering, Environmental Sciences +17
Inhibition of Clinically Relevant Mutant Variants of HIV-1 by Quinazolinone Non-Nucleoside Reverse Transcriptase Inhibitors
Jeffrey W. Corbett, Soo S. Ko, James D. Rodgers et al. · Journal of Medicinal Chemistry · 2000 · 301 citations · Full text
Medicine, Medicinal Chemistry, Pharmacology +16
Enantioselective Synthesis of Janus Kinase Inhibitor INCB018424 via an Organocatalytic Aza-Michael Reaction
Qiyan Lin, David Meloni, Yongchun Pan et al. · Organic Letters · 2009 · 170 citations
Pharmacy, Chemistry, Medicinal Chemistry +11
1–5 of 42